Nov 2026· Updates in Surgery· 0 citations· 43 references
Medicine
TL;DR
Glycemic improvement after bariatric surgery is associated with complex metabolic interactions involving insulin sensitivity, incretin modulation, and inflammatory changes, which support the role of bariatric and metabolic surgery as a metabolic and immunometabolic intervention.
Abstract
Background
Bariatric and metabolic surgery is one of the most effective treatments for severe obesity and type 2 diabetes mellitus (T2DM), promoting metabolic changes beyond weight loss. However, the biochemical determinants of postoperative glycemic response remain incompletely understood.
Methods
A scoping review was conducted following PRISMA-ScR guidelines. PubMed/MEDLINE and Scopus were searched for studies published between 2016 and 2025 evaluating metabolic and biochemical variables associated with glycemic outcomes after bariatric surgery.
Results
Twenty-two studies were included, comprising eight randomized controlled trials and fourteen cohort studies. Bariatric surgery was consistently associated with reductions in HbA1c and significant rates of T2DM remission. Improvements in insulin resistance (HOMA-IR), beta-cell function, and incretin response-particularly GLP-1-were associated with better outcomes. Reductions in inflammatory markers, including IL-6, IFN-γ, and TNF-α, were also reported.
Conclusion
Glycemic improvement after bariatric surgery is associated with complex metabolic interactions involving insulin sensitivity, incretin modulation, and inflammatory changes. These findings support the role of bariatric and metabolic surgery as a metabolic and immunometabolic intervention, although the descriptive design of a scoping review precludes causal inference.
This article summarizes data from clinical studies, randomized controlled trials, and systematic reviews published in leading international databases in recent years, allowing for an evaluation of the efficacy and safety of bariatric surgery in patients with obesity and T2DM.
M. Gulov, K. K. Kobilzoda, D. S. Salimov et al.· Health care of Tajikistan· 0 citations
The evidence supports a shift from a model of inevitable progression toward one of potentially reversible metabolic dysfunction, with important implications for early, remission-oriented care.
Metabolic and bariatric surgery (MBS) is an effective treatment for patients with obesity and type 2 diabetes (T2D). Preoperative T2D severity may influence perioperative safety and T2D outcomes after MBS.
A retrospective analysis of a single-center database of adults with T2D who underwent MBS between Jan...
Hila Butbul, Jawad Tome, J. B. Yuval et al.· Langenbeck's archives of sur...· 0 citations
The expanding efficacy of incretin-based pharmacotherapy has changed the comparison between metabolic and bariatric surgery and medical obesity treatment. This narrative critical review examines weight-loss durability, control of obesity-related complications, comparative evidence, and treatment selection using clinica...
Karoline Sabatine Volpato, Rafael Berger Simionato, R. Farias et al.· International Health Science...· 0 citations
Among adults with obesity and T2D, MBS was associated with greater %TWL, higher glycaemic normalization, and lower 5-year risks of nephropathy, retinopathy, MACE, and all-cause mortality compared with real-world initiation of OMMs among patients in clinical equipoise, supporting the role of MBS as a durable therapy in...
A. Gillikin, Emily P. Rabinovich, A. Nimeri et al.· British Journal of Surgery· 0 citations
OBJECTIVE
this study aimed to evaluate the impact of bariatric-metabolic surgery combined with continuity of care on the remission of metabolic diseases in obese patients.
METHODS
clinical data from 120 obese patients treated between January 2021 and January 2023 were retrospectively analyzed. All patients underwent...
Yue'e Du, Ling-Ling Zhou, Lei Tang et al.· Nutrición Hospitalaria· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.